The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

NCT04422678 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Imatinib Mesylate
DRUG: Standard of Care

Sponsor

Alexandria University

Collaborators

[object Object]